VIRX

Viracta Therapeutics, Inc. is a precision oncology company focused on the treatment and prevention of virus-associated cancers. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label phase II basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II trial for the treatment of EBV+recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its Vecabrutinib is a selective, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK). VRx-510 is its preclinical-stage PDK-1 inhibitor. It is also investigating in pre-clinical studies the use of its epigenetic drug candidate, nanatinostat.